Antengene Corporation Limited (HK:6996) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Antengene Corporation Limited has announced that its drug XPOVIO, used to treat relapsed or refractory diffuse large B-cell lymphoma, will be included in China’s 2024 National Reimbursement Drug List. This inclusion marks a significant milestone for Antengene, potentially enhancing its market presence and financial performance. Investors and shareholders may find this development promising as it could lead to increased adoption and sales of XPOVIO in the region.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue